79 results
8-K
EX-99.1
YMAB
Y-Mabs Therapeutics Inc
18 Oct 23
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
4:09pm
Information (https://labeling.ymabs.com/danyelza) for complete Boxed Warning and other important safety information.
About Y-mAbs
Y-mAbs is a commercial
8-K
EX-10.2
YMAB
Y-Mabs Therapeutics Inc
18 Oct 23
Y-mAbs Names Michael Rossi as President and Chief Executive Officer and Director
4:09pm
or resulting from research, development, testing, trials, studies (including regarding product safety, efficacy or use), new products, business and operational … Commission, the Equal Employment Opportunity Commission, the Occupational Safety and Health Administration, and the National Labor Relations Board
8-K
EX-99.1
gy8vx9 z026hl3h
18 Oct 23
Y-mAbs Therapeutics Announces U.S. FDA Clearance of Investigational New Drug Application for CD38-SADA
9:00am
8-K
EX-99.1
3uv8bvlye j4d
26 May 23
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
5:05pm
8-K
EX-99.2
adh2igefc 9nap
26 May 23
Y-mAbs Announces Presentation of Naxitamab Data at ASCO
5:05pm
8-K
EX-99.1
webwdp
23 May 23
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in Brazil
9:41am
8-K
EX-99.1
ctg457o
18 Apr 23
Y-mAbs Announces Presentation of Naxitamab data at AACR
9:19am
8-K
EX-99.1
lvh40klx9d
5 Apr 23
Y-mAbs Announces First Patient Dosed in Phase 1 Clinical Trial of GD2-SADA
9:09am
8-K
EX-99.1
lj7enppd4 jt
21 Dec 22
Y-mAbs Announces Partnership regarding Early Access Program for DANYELZA (naxitamab-gqgk) in Europe
2:16pm
8-K
EX-99.1
8lcg6 ok4
14 Dec 22
Y-mAbs Announces Pipeline Update
9:05am
8-K
EX-99.1
czb y8gz08
8 Dec 22
Y-mAbs’ DANYELZA® (naxitamab-gqgk) for the Treatment of High-Risk Neuroblastoma approved in China
10:15am